Merck and Isomorphic Labs team up to find new drugs
The partnership merges Isomorphic's proprietary drug design engine with Merck's wet lab data, with Merck leading preclinical and clinical development for undisclosed oncology targets.
- Field
- drugs and trials
- What they did
- Pharmaceutical company Merck and AI startup Isomorphic Labs have partnered to develop drug candidates for cancer using a technology that models how molecules bind to proteins.
- Why it matters
- The collaboration aims to combine Merck's existing wet lab data with Isomorphic's proprietary drug design engine to discover new small molecule candidates for a high-interest cancer target.
#merck#isomorphic labs#oncology#drug discovery#ai modeling#clinical trials



